These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

813 related articles for article (PubMed ID: 34363606)

  • 81. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure.
    Ghosh RK; Ghosh GC; Gupta M; Bandyopadhyay D; Akhtar T; Deedwania P; Lavie CJ; Fonarow GC; Aneja A
    Am J Cardiol; 2019 Dec; 124(11):1790-1796. PubMed ID: 31627834
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
    Giorgino F; Vora J; Fenici P; Solini A
    Cardiovasc Diabetol; 2020 Nov; 19(1):196. PubMed ID: 33222693
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease.
    Masuda T; Nagata D
    Hypertens Res; 2023 May; 46(5):1195-1201. PubMed ID: 36849579
    [TBL] [Abstract][Full Text] [Related]  

  • 87. How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?
    Neumiller JJ; Kalyani RR
    Clin J Am Soc Nephrol; 2019 Nov; 14(11):1667-1669. PubMed ID: 31575617
    [No Abstract]   [Full Text] [Related]  

  • 88. Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
    De Nicola L; Cozzolino M; Genovesi S; Gesualdo L; Grandaliano G; Pontremoli R
    J Nephrol; 2022 Jul; 35(6):1605-1618. PubMed ID: 35583597
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.
    Mima A
    Adv Ther; 2022 Aug; 39(8):3488-3500. PubMed ID: 35751762
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 91. Use of SGLT-2 Inhibitors to Treat Chronic Kidney Disease in Primary Care.
    Bakris G
    J Fam Pract; 2022 Jul; 71(6 Suppl):S88-S93. PubMed ID: 35960952
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
    Thomson SC; Vallon V
    Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
    [TBL] [Abstract][Full Text] [Related]  

  • 93. SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study.
    Chan GC; Ng JK; Chow KM; Szeto CC
    Diabetes Res Clin Pract; 2023 Jan; 195():110200. PubMed ID: 36481225
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.
    Khoo CM; Deerochanawong C; Chan SP; Matawaran B; Sheu WH; Chan J; Mithal A; Luk A; Suastika K; Yoon KH; Ji L; Man NH; Pollock C
    Diabetes Obes Metab; 2021 Feb; 23(2):299-317. PubMed ID: 33155749
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
    Heerspink HJL; Sjöström CD; Jongs N; Chertow GM; Kosiborod M; Hou FF; McMurray JJV; Rossing P; Correa-Rotter R; Kurlyandskaya R; Stefansson BV; Toto RD; Langkilde AM; Wheeler DC;
    Eur Heart J; 2021 Mar; 42(13):1216-1227. PubMed ID: 33792669
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease.
    Almaimani M; Sridhar VS; Cherney DZI
    Curr Opin Nephrol Hypertens; 2021 Sep; 30(5):474-481. PubMed ID: 34074889
    [TBL] [Abstract][Full Text] [Related]  

  • 97. SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis.
    Mavrakanas TA; Tsoukas MA; Brophy JM; Sharma A; Gariani K
    Sci Rep; 2023 Sep; 13(1):15922. PubMed ID: 37741858
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Benefit of combination therapy with dapagliflozin and eplerenone on cardiac function and fibrosis in rats with non-diabetic chronic kidney disease.
    Soulié M; Stephan Y; Durand M; Lima-Posada I; Palacios-Ramírez R; Nicol L; Lopez-Andres N; Mulder P; Jaisser F
    Sci Rep; 2024 Oct; 14(1):23955. PubMed ID: 39397161
    [TBL] [Abstract][Full Text] [Related]  

  • 99. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.
    Sarafidis P; Ferro CJ; Morales E; Ortiz A; Malyszko J; Hojs R; Khazim K; Ekart R; Valdivielso J; Fouque D; London GM; Massy Z; Ruggenenti P; Porrini E; Wiecek A; Zoccali C; Mallamaci F; Hornum M
    Nephrol Dial Transplant; 2019 Feb; 34(2):208-230. PubMed ID: 30753708
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.